The global contrast enhanced ultrasound market is gaining steady momentum as healthcare providers increase the use of real-time, radiation-free imaging for lesion characterization, perfusion assessment, cardiac evaluation, vascular imaging, and cancer diagnostics. The market was valued at USD 2.19 billion in 2025 and is projected to grow from USD 2.30 billion in 2026 to USD 3.44 billion by 2034, registering a CAGR of 5.14% during the forecast period 2026–2034.
Clinical interest in contrast-enhanced ultrasound continues to strengthen as microbubble-based contrast agents improve visualization of blood flow and tissue perfusion without exposing patients to ionizing radiation. Advances in contrast delivery systems, imaging software, automated quantification, and targeted microbubble technologies are also broadening the role of CEUS across hospital and outpatient imaging environments.
Market Size (2025): USD 2.19 Billion
Market Size (2026): USD 2.30 Billion
CAGR (Forecast Period): 5.14%
Forecast Year: 2034
Projected Market Size (2034): USD 3.44 Billion
Dominant Region: North America
Fastest Growing Region: Europe
Contrast Enhanced Ultrasound Market Overview
Contrast-enhanced ultrasound combines conventional sonography with intravenously administered gas-filled microbubbles that improve the visualization of vascular structures and tissue perfusion. The technology allows clinicians to assess enhancement patterns in real time and supports diagnostic evaluation across liver, cardiac, vascular, oncology, and other imaging applications.
The market is gradually shifting toward more standardized CEUS workflows. Dedicated contrast delivery systems, advanced image-processing tools, and quantitative software are helping imaging departments improve examination consistency while reducing operator-dependent variability.
CEUS is also moving beyond traditional liver and cardiac applications. Greater clinical attention to breast imaging, superficial organs, oncology, and molecular imaging is creating a broader application base for ultrasound systems, contrast agents, and specialized imaging software.
Contrast Enhanced Ultrasound Market Growth Drivers
Demand for radiation-free diagnostic imaging remains an important growth factor for the contrast enhanced ultrasound market. Ultrasound does not use ionizing radiation, which makes CEUS valuable for patients requiring repeated examinations, lesion surveillance, and follow-up imaging.
Clinical evidence also supports the diagnostic value of CEUS in focal liver lesion assessment. A study involving 146 focal liver lesions showed that CEUS alone classified 89.0% of lesions as benign or malignant and provided specific lesion identification in 80.8% of cases. These capabilities can reduce the need for additional CT examinations in selected diagnostic pathways.
Healthcare providers are also placing stronger emphasis on diagnostic cost control. A multicenter study covering 575 focal liver lesions found that CEUS correctly differentiated benign from malignant lesions in 97.2% of cases and generated savings of approximately €162 per patient compared with conventional diagnostic pathways.
The combination of diagnostic performance, real-time imaging, lower radiation exposure, and potential cost advantages continues to strengthen the clinical case for wider CEUS adoption.
Contrast Enhanced Ultrasound Market Challenges
Reimbursement uncertainty remains a practical challenge for CEUS providers. Hospitals must consider the cost of contrast agents, compatible imaging systems, software, clinical staff, and examination time when determining whether CEUS services can be expanded economically.
The 2026 U.S. Medicare outpatient payment for certain noncardiac CEUS procedures increased to USD 243.77, highlighting the importance of reimbursement structures in hospital investment and service planning.
Clinical workflow complexity can also slow adoption. CEUS examinations may require intravenous access, precisely timed imaging, contrast administration, specialist interpretation, and coordination between imaging and clinical teams.
Published liver CEUS implementation experience has also indicated that examinations may require two staff members and additional scheduling time. These operational requirements can affect examination capacity and lengthen purchasing decisions for hospitals evaluating CEUS programs.
Contrast Enhanced Ultrasound Market Opportunities
Artificial intelligence and automated CEUS quantification are creating new commercial opportunities for ultrasound manufacturers, imaging software companies, and contrast-agent developers. Automated analysis can help standardize perfusion measurement, lesion assessment, reporting, and follow-up comparisons across examinations.
Bracco's VueBox platform already supports quantitative parameters including wash-in rate, peak enhancement, rise time, time-to-peak, and area-under-the-curve from dynamic contrast-enhanced ultrasound clips. Cross-platform calibration capabilities also create opportunities for software providers to support multiple ultrasound systems within hospital networks.
Theranostic applications represent another developing opportunity. Biotechnology companies, pharmaceutical manufacturers, microbubble developers, and ultrasound system providers can explore the use of microbubbles for targeted therapeutic delivery alongside diagnostic imaging.
Clinical research in 2026 examined ultrasound combined with microbubbles in invasive breast cancer and investigated microbubble-assisted drug delivery in hepatocellular carcinoma. Continued clinical development could create new applications beyond conventional diagnostic CEUS.
Contrast Enhanced Ultrasound Market Segment Analysis
The equipment segment dominated the contrast enhanced ultrasound market with a market share of 61.8% in 2025. Its leadership is supported by the widespread use of advanced ultrasound systems for liver imaging, cardiac assessment, vascular evaluation, and other diagnostic procedures.
The contrast agent segment is expected to register the fastest CAGR of 7.89% during the forecast period 2026–2034. Wider clinical use of microbubble-based agents for lesion characterization and blood-flow assessment is supporting segment expansion.
By type, the non-targeted segment held the largest market share of 72.6% in 2025. These agents remain widely used for conventional vascular and organ imaging because microbubbles circulate through the bloodstream without binding to specific molecular targets.
The targeted segment is projected to grow at the fastest CAGR of 8.31% during the forecast period 2026–2034. Continued research into molecular imaging and biomarker-specific contrast mechanisms supports its long-term potential.
By end-use, hospitals dominated the market with a share of 56.7% in 2025. Large patient volumes, advanced imaging infrastructure, specialist availability, and multidisciplinary use across radiology, cardiology, oncology, and emergency care strengthen the hospital segment.
Ambulatory diagnostic centers are expected to register the fastest CAGR of 7.91% during the forecast period 2026–2034 as outpatient imaging expands and compact ultrasound systems become more widely used.
Contrast Enhanced Ultrasound Market Regional Analysis
North America dominated the contrast enhanced ultrasound market with a share of 39.5% in 2025. Advanced imaging infrastructure, established hospital networks, access to CEUS-capable ultrasound systems, and broader availability of specialist diagnostic services support regional leadership.
The U.S. market is influenced by demographic change, with the Census Bureau projecting that one in five Americans will be of retirement age by 2030. A larger older population may increase the need for liver, cardiac, vascular, and cancer-related imaging services.
Canada is also experiencing significant population aging. Statistics Canada projects the population aged 65 and older to reach approximately 9.4 million by 2030, compared with around 8.1 million in 2025, supporting longer-term diagnostic imaging requirements.
Europe is expected to register the fastest CAGR of 8.12% during the forecast period 2026–2034. Greater emphasis on early diagnosis, non-invasive imaging, and cancer detection is supporting broader CEUS adoption.
England's National Cancer Plan targets at least a 20-percentage-point increase in cancers diagnosed at stages 1 and 2 by 2035 compared with 2019. Germany's Federal Statistical Office also projects the population aged 67 and older to reach at least 20.5 million by the end of the 2030s.
Asia Pacific accounted for a 22.6% market share in 2025 and is projected to grow at a CAGR of 7.68% during 2026–2034. Healthcare infrastructure expansion, cancer diagnosis initiatives, and investment in advanced medical imaging are strengthening regional market development.
China's Cancer Prevention and Control Action Plan targets an overall five-year cancer survival rate of 46.6% by 2030 and an early-diagnosis rate of at least 55% for key cancers in high-incidence areas. India is also preparing for an estimated annual cancer burden of around 2 million new cases by 2030, supporting the need for expanded diagnostic capabilities.
Contrast Enhanced Ultrasound Market Competitive Landscape
The contrast enhanced ultrasound market is moderately consolidated, with global diagnostic imaging manufacturers, ultrasound system developers, contrast-agent companies, and specialized medical imaging firms competing across hospital and diagnostic settings.
GE HealthCare, Siemens Healthineers AG, Bracco Diagnostics Inc., Lantheus Medical Imaging, Inc., and Shenzhen Mindray Bio-Medical Electronics Co. Ltd. are estimated to collectively account for approximately 55–60% of the global market.
Established companies compete through imaging performance, regulatory approvals, installed equipment bases, software capabilities, contrast-agent compatibility, clinical validation, and hospital relationships. Emerging and regional companies focus on portable ultrasound systems, specialized applications, competitive pricing, workflow software, localized service, and customization.
Key companies operating in the contrast enhanced ultrasound market include:
GE HealthCare
Siemens Healthineers AG
Esaote SPA
Lantheus Medical Imaging, Inc.
Bracco Diagnostics Inc.
Shenzhen Mindray Bio-Medical Electronics Co. Ltd.
NanoPET Pharma GmbH
Recent Developments in the Contrast Enhanced Ultrasound Market
Clinical workflow standardization continued to advance in 2026 as dedicated CEUS delivery technologies moved closer to routine use. Bracco's VueJect received U.S. FDA 510(k) clearance on August 3, 2026, under device number K262115, alongside Health Canada Medical Device License No. 115637.
The system supports continuous administration of ultrasound contrast agents during cardiac imaging and can help improve consistency during contrast-enhanced examinations.
Clinical standardization is also progressing in breast imaging. A 2026 breast CEUS consensus developed by an expert panel of 52 listed authors addressed acquisition methods, qualitative and quantitative enhancement assessment, interpretation, and standardized reporting.
Research into therapeutic microbubble applications also advanced during 2026, including clinical investigation of ultrasound combined with microbubbles in invasive breast cancer and studies involving enhanced drug delivery in hepatocellular carcinoma.
Click to Read the Complete Insights & Report: https://straitsresearch.com/report/contrast-enhanced-ultrasound-market
Contrast Enhanced Ultrasound Market Future Outlook
The contrast enhanced ultrasound market is expected to expand steadily as healthcare systems place greater emphasis on radiation-free imaging, early diagnosis, efficient lesion characterization, and lower-cost diagnostic pathways.
Greater integration of artificial intelligence, standardized contrast delivery, quantitative imaging software, and advanced microbubble technologies is expected to improve consistency and broaden CEUS applications across hospitals and outpatient centers.
New clinical applications in oncology, breast imaging, molecular imaging, targeted microbubbles, and therapeutic delivery could further extend the role of CEUS beyond established diagnostic uses. Market participants that combine imaging hardware, contrast agents, workflow software, and clinical evidence are likely to strengthen their position as CEUS adoption becomes more structured across healthcare systems.
About Straits Research
Straits Research is a global market intelligence and consulting company that provides industry research, strategic insights, competitive intelligence, and data-driven analysis across multiple sectors. The company supports businesses, investors, and decision-makers with market sizing, forecasts, trend analysis, competitive assessments, and strategic intelligence designed to identify emerging opportunities and support informed business decisions.
Top comments (0)